Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

BACKGROUND: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Lattanzi, Michael, Han, Joseph, Moran, Una, Utter, Kierstin, Tchack, Jeremy, Sabado, Rachel Lubong, Berman, Russell, Shapiro, Richard, Huang, Hsin-Hui, Osman, Iman, Bhardwaj, Nina, Pavlick, Anna C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5958403/
https://ncbi.nlm.nih.gov/pubmed/29773080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0345-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi